Objective responses included: 2 PRs among 3 MSI-H patients with both responders having pancreatic ductal adenocarcinoma. One patient with MSI-H PDAC was initially misclassified as MSI-H small bowel ...

IO Biotech (IOBT) announced data from the NSCLC cohort in the company’s Phase 2 basket trial of IO102-IO103, the company’s lead investigational candidate, given in combination with Merck’s anti-PD-1 ...

Good afternoon, everyone. Thank you for standing by. Welcome to CytomX Therapeutics third quarter, 2024 Financial results call. Please be advised that today's call is being recorded. I would now like ...

The deal-making activity signals Merck’s determination to stay at the forefront of cancer immunotherapy with new medicines that could complement Keytruda and broaden its portfolio. Janux says ...

The medicine continues to grind out new indications -- it is currently awaiting one in advanced pancreatic neuroendocrine tumor ... That beat Merck's cancer immunotherapy Keytruda. To put this into ...

Keytruda in early-stage triple-negative breast cancer led to immune-related adverse effects, including severe GI issues and ...

BioNTech’s willingness to significantly increase its upfront bet on BNT327 reflects a belief the candidate could set a new ...

Ohio State cancer researchers and surgeons are developing and deploying cutting-edge techniques to help patients.

The gut microbiome's impact on pancreatic cancer highlights potential for early screening and fecal microbiota ...

Researchers at the University of Virginia have discovered a new mechanism driving drug resistance in pancreatic ductal ...

Merck & Co’s immuno-oncology drug Keytruda (pembrolizumab ... with expected sales of $10 billion. The breast cancer drug Ibrance (palbociclib), ranked eighth, has emerged as a big earner ...

In drug discovery, targeted protein degradation is a method that selectively eliminates disease-causing proteins.